Sam Murphy
Director/Board Member at VIRACTA THERAPEUTICS, INC.
Net worth: - $ as of 2024-06-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ivor Royston | M | 79 |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 17 years |
| Daniel Chevallard | M | 44 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 years |
| Roger Pomerantz | M | 67 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 years |
| Melody Burcar | F | 41 | 2 years | |
| Gur Roshwalb | M | 55 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 years |
| Barry Simon | M | 59 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 7 years |
| Michael Huang | M | 50 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 5 years |
| Mark Rothera | M | 61 | 2 years | |
| Constantine Theodoropulos | M | - |
Go Therapeutics, Inc.
 Go Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Go Therapeutics, Inc. manufactures and develops cancer therapeutics. The company was founded by Constantine Theodoropulos and is headquartered in Cambrige, MA. | - |
| Jane Chung | F | 53 | 2 years | |
| Stephen Rubino | M | 65 | 3 years | |
| Thomas Darcy | M | 74 | 3 years | |
| Flavia Borellini | M | 65 | 3 years | |
| Jane Barlow | M | 63 | 3 years | |
| Ashleigh Barreto | F | - | 3 years | |
| Jeffrey Bryan Jump | M | 65 |
M.A. Med Alliance SA
 M.A. Med Alliance SA Packaged SoftwareTechnology Services M.A. Med Alliance SA is a company based in Nyon, Switzerland that specializes in developing innovative technology and commercializing advanced drug device combination products for the treatment of coronary and peripheral artery disease. The Swiss company's flagship product is the Selution SLR™ DEB, which is a novel sirolimus-eluting balloon platform technology. The CEO of the company is Jeffrey Bryan Jump. | - |
| Jim Woody | M | 81 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | - |
| Robert Wills | M | 70 |
Go Therapeutics, Inc.
Go Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Go Therapeutics, Inc. manufactures and develops cancer therapeutics. The company was founded by Constantine Theodoropulos and is headquartered in Cambrige, MA. | 7 years |
| Ayman El-Guindy | M | - | 3 years | |
| Donald Strickland | M | - | - | |
| Richard Ghalie | M | 66 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 9 years |
| Darrel Cohen | M | 59 | 1 years | |
| Biljana Nadjsombati | F | - | 3 years | |
| Patric Nelson | M | - | 3 years | |
| Sam Murphy | M | - |
M.A. Med Alliance SA
M.A. Med Alliance SA Packaged SoftwareTechnology Services M.A. Med Alliance SA is a company based in Nyon, Switzerland that specializes in developing innovative technology and commercializing advanced drug device combination products for the treatment of coronary and peripheral artery disease. The Swiss company's flagship product is the Selution SLR™ DEB, which is a novel sirolimus-eluting balloon platform technology. The CEO of the company is Jeffrey Bryan Jump. | - |
| Yan Zhao | M | - |
M.A. Med Alliance SA
M.A. Med Alliance SA Packaged SoftwareTechnology Services M.A. Med Alliance SA is a company based in Nyon, Switzerland that specializes in developing innovative technology and commercializing advanced drug device combination products for the treatment of coronary and peripheral artery disease. The Swiss company's flagship product is the Selution SLR™ DEB, which is a novel sirolimus-eluting balloon platform technology. The CEO of the company is Jeffrey Bryan Jump. | - |
| Simos Kedikoglou | M | - |
M.A. Med Alliance SA
M.A. Med Alliance SA Packaged SoftwareTechnology Services M.A. Med Alliance SA is a company based in Nyon, Switzerland that specializes in developing innovative technology and commercializing advanced drug device combination products for the treatment of coronary and peripheral artery disease. The Swiss company's flagship product is the Selution SLR™ DEB, which is a novel sirolimus-eluting balloon platform technology. The CEO of the company is Jeffrey Bryan Jump. | - |
| Scott Addonizio | M | - |
M.A. Med Alliance SA
M.A. Med Alliance SA Packaged SoftwareTechnology Services M.A. Med Alliance SA is a company based in Nyon, Switzerland that specializes in developing innovative technology and commercializing advanced drug device combination products for the treatment of coronary and peripheral artery disease. The Swiss company's flagship product is the Selution SLR™ DEB, which is a novel sirolimus-eluting balloon platform technology. The CEO of the company is Jeffrey Bryan Jump. | - |
| Cheryl A. Madsen | F | - | - | |
| Thayer White | M | - |
Go Therapeutics, Inc.
Go Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Go Therapeutics, Inc. manufactures and develops cancer therapeutics. The company was founded by Constantine Theodoropulos and is headquartered in Cambrige, MA. | - |
| Gregory L. Chase | M | - |
Go Therapeutics, Inc.
Go Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Go Therapeutics, Inc. manufactures and develops cancer therapeutics. The company was founded by Constantine Theodoropulos and is headquartered in Cambrige, MA. | - |
| Stewart M. Brown | M | - | 2 years | |
| Joel Crater | M | - |
M.A. Med Alliance SA
M.A. Med Alliance SA Packaged SoftwareTechnology Services M.A. Med Alliance SA is a company based in Nyon, Switzerland that specializes in developing innovative technology and commercializing advanced drug device combination products for the treatment of coronary and peripheral artery disease. The Swiss company's flagship product is the Selution SLR™ DEB, which is a novel sirolimus-eluting balloon platform technology. The CEO of the company is Jeffrey Bryan Jump. | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nicole Onetto | M | 71 | 2 years | |
| Lisa Rojkjaer | M | 58 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 3 years |
| Shelly Vandertie | F | - | - | |
| Michael M. Mueller | M | - | 2 years | |
| David Slack | M | 61 |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 32 | 84.21% |
| Switzerland | 6 | 15.79% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sam Murphy
- Personal Network
